Immucell Corp /De/ICCC

ImmuCell Corporation, the Delaware-registered animal-health outfit behind the calf-scours prevention brand First Defense, just reported a quarter that looked like a textbook case study in micro-cap triumph: $10.4 million of revenue for the three months to 31 March 2026 versus $6.4 million a year earlier, alongside $1.9 million of net income and $3.6 million of operating cash. The party trick was achieved while carrying $8.7 million of inventory and a single customer owning 41 % of sales, a concentration that would make even the sturdiest boutique investment bank reach for the Dramamine. (source: ICCC 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/811641/000143774926017045/iccc20260331_10q.htm)

The company’s latest 8-K reveals that ImmuCell has mothballed the Re-Tain manufacturing line and repurposed the facility for First Defense output, a strategic pivot that sounds smoother on paper than it feels in the chilled corridors of the factory floor. Capital expenditure for the quarter was a modest $177 k-cheap enough to keep the CFO’s slide deck polite, but barely visible against $8.7 million of inventory. Research and development outlays clocked in at $318 k, a figure that implies the firm is keeping its powder dry while the bovine world keeps demanding more shots in the dark. (source: ICCC 8-K, 2026-06-10, https://www.sec.gov/Archives/edgar/data/811641/000143774926020154/iccc20260608_8k.htm)

ImmuCell’s balance sheet offers a rare mix of promise and constraint: $44.1 million of assets against $15 million of liabilities, $6.8 million of cash, and $29.1 million of shareholders’ equity. The numbers read like a small-cap fairy tale-until you notice the company has neither raised capital nor repurchased shares in the last year and is carrying 9.0 million diluted shares to boot. Diluted EPS of $0.21 therefore arrives with a quiet asterisk: the share count is drifting upward while the cash pile is drifting sideways, and the biggest customer’s order book remains the single point of failure. (source: ICCC 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/811641/000143774926017045/iccc20260331_10q.htm)

ImmuCell’s product rail is straightforward: First Defense calf scours prevention, a serum designed to stop neonatal diarrhoea from turning a Holstein calf into a veterinary write-off. The company’s own pages trumpet the science and sell the education kit, but the filings remain silent on unit volumes, gross margins, or any signed multi-year supply agreement beyond the single large customer. Until the 10-Q starts breaking down segment economics or at least naming the 41 % customer, the platform story will continue to outshine the balance-sheet reality. (source: Scours Prevention Products, https://immucell.com/scours-prevention-products/)

The company’s 8-K dance card over the past two months reads like a choreography of strategic reallocation: in December 2025 and January 2026 ImmuCell suspended in-house Re-Tain manufacturing, swapped the lines to First Defense expansion, and then issued an 8-K on 10 June 2026 to confirm the facility conversion. The sequence is neat; the missing link is a public disclosure of pricing power, volume growth, or new customer wins. Until those appear, the market is being asked to value a story rather than a business. (source: ICCC 8-K, 2026-06-10, https://www.sec.gov/Archives/edgar/data/811641/000143774926020154/iccc20260608_8k.htm)

For readers who like their filings with a side order of colour, the SEC’s EDGAR index for CIK 811641 serves up the full chronology of ImmuCell’s corporate paparazzi moments-from May’s unaudited quarterly results to July’s 8-K on capacity allocation. The index is free, the data are public, and the narrative remains the company’s to write. (source: ICCC SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=811641)